This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
by Zacks Equity Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.
Verrica Pharmaceuticals Inc. (VRCA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
by Zacks Equity Research
Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Down 65% in 4 Weeks, Here's Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc. (VRCA)
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Verrica Pharmaceuticals Inc. (VRCA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 Weeks
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA
by Zacks Equity Research
Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
by Zacks Equity Research
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
by Ekta Bagri
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
by Zacks Equity Research
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
by Zacks Equity Research
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.
Verrica (VRCA) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study
by Zacks Equity Research
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
by Zacks Equity Research
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
Will Verrica Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.